DB-1310 by Duality Biologics (Shanghai) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Novel Biannual Antihypertensive Shows Potential for Combination Therapy

ATLANTA — The novel RNA silencer zilebesiran reduced blood pressure (BP) when added to a diuretic, calcium channel blocker, or maximum-dose angiotensin receptor blocker, the

April 10, 2024

Diets impact Parkinson’s motor symptoms, supplements show no benefit, study finds

Meta-analysis reveals that diets like the Mediterranean and ketogenic can improve motor function in Parkinson’s disease patients, although dietary supplements do not enhance UPDRS or

February 22, 2024

Aerovate’s stock craters after PAH drug fails Phase 2 study

Aerovate Therapeutics’ mid-stage treatment for pulmonary arterial hypertension failed to meaningfully improve patients’ blood pressure compared to placebo across three doses, sending the company’s shares

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.